Accelr8 Announces Presentation of Preliminary Results in Pilot ICU Study, Plus Advances in Product Engineering
February 22 2011 - 8:00AM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) announced
that clinical research collaborators at the Denver Health Medical
Center received notification of acceptance for presentation of
interim research results at the annual meeting of the American
Thoracic Society (www.ats.org). The meeting will be held in May.
The presentation will describe “early look” results from a clinical
pilot study that uses Accelr8’s BACcel™ rapid diagnostic system.
The research uses specimens from ICU patients under an
Institutional Review Board approved protocol with informed patient
consent. Specific aims include comparison of diagnostic speed and
accuracy against results from standard laboratory culturing.
The BACcel™ system analyzes live microbial cells extracted
directly from a patient specimen and eliminates the need for days
of laboratory cultures. In previous research, the system
demonstrated the ability to report quantitative identification
within two hours after obtaining a specimen, and major drug
resistance expression types within a total of six hours. Standard
culturing methods require 2-3 days, which is too late to improve
outcomes for critically ill patients who acquire drug-resistant
infections with endemic hospital pathogens.
The company also disclosed that it has begun to integrate its
automated microscopy and fluidic robotics into a single instrument.
The company established technical milestones in the second calendar
quarter for specialty suppliers to demonstrate subsystems and
integration feasibility. Based on supplier input, management
believes that “alpha” systems will become available to
international key opinion leaders in about one year.
According to David Howson, Accelr8’s president, “these two
events reflect the substantial progress we’ve made in field studies
and in making the transition to a fully automated hospital product.
The May presentation offers the first exposure to the Pulmonary
Medicine community for the BACcel™ system. The study itself is
designed to answer important questions that researchers have not
previously been able to address because there has been no method to
quickly analyze emergent infections. Our system is now closing that
critical gap,” Howson concluded.
In other news, the January issue of the Bowser Report featured
Accelr8 as the Stock of the Month. Copies of the report are
available at www.thebowserreport.com.
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative
materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection.
Accelr8 is developing a rapid analytical platform for infectious
pathogens, the BACcel™ system, based on its innovative surface
coatings, assay processing, and detection technologies. In
addition, Accelr8 licenses certain of its proprietary technology
for use in applications outside of Accelr8’s own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024